Innovation Spending: A Tale of Two Companies

A Decade of R&D Investment

In the ever-evolving landscape of biotechnology and pharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, CRISPR Therapeutics AG and Perrigo Company plc have demonstrated contrasting approaches to R&D investment.

CRISPR Therapeutics AG, a pioneer in gene editing, has shown a remarkable increase in R&D expenses, growing from a modest $1.5 million in 2014 to a staggering $462 million in 2022. This represents an impressive growth rate of over 30,000%, underscoring their aggressive pursuit of cutting-edge genetic therapies.

Conversely, Perrigo Company plc, a leader in over-the-counter health products, has maintained a more stable R&D expenditure, peaking at $219 million in 2018 but gradually declining to $122 million by 2023. This steady approach reflects their focus on incremental innovation and product line expansion.

These divergent strategies highlight the dynamic nature of innovation in the biotech and pharmaceutical sectors, where companies must balance risk and reward in their quest for breakthroughs.